X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BST-236 (aspacytarabine) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. Aspacytarabine enables high-dose therapy with lower systemic exposure to free cytarabine.
Lead Product(s): Aspacytarabine,Venetoclax
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
Aspacytarabine (BST-236), is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine for the treatment of acute myeloid leukemia.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Phase 2b clinical trial of BST-236 (Aspacytarabine), showed a complete remission rate of 37%, of which 50% were minimal residual disease negative. Rapid complete hematological recovery was observed with a median time of 25 days for complete neutrophil recovery.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biosight
Deal Size: $50.0 million Upfront Cash: $50.0 million
Deal Type: Merger July 06, 2021
Details:
The data reported to date provide compelling evidence that aspacytarabine, with a differentiated mechanism that enables high-dose chemotherapy with reduced toxicity, has the potential to transform standard of care for AML patients.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
Aspacytarabine, Biosight’s lead product candidate, is a novel antimetabolite designed to provide the benefit of intensive chemotherapy while reducing the associated systemic toxicity.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
These additional proceeds will be used to advance the clinical development of Biosight’s lead asset BST-236 (aspacytarabine), currently being investigated in a multi-center Phase 2b study in the U.S.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Israel Biotech Fund
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing December 02, 2020
Details:
The presentation will present updated clinical data from the Company’s ongoing Phase 2b trial evaluating aspacytarabine (BST-236) as a single-agent first-line AML therapy for patients unfit for standard chemotherapy.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
BST-236, Biosight’s lead product candidate, is a novel antimetabolite, designed to provide the benefit of intensive chemotherapy while avoiding much of its toxicity.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2020
Details:
GFM will sponsor a Phase 2 clinical trial to evaluate BST-236, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory MDS or acute myeloid leukemia (AML).
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: BST-236
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Groupe Francophone
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 21, 2020
Details:
Proceeds support clinical advancement of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity.
Lead Product(s): Aspacytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Israel Biotech Fund
Deal Size: $19.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
